Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …
genomic landscapes and biological functions, the treatment of PCa continues to improve …
Nanotechnological approaches in prostate cancer therapy: integration of engineering and biology
Nanocarriers have received special attention in biomedicine for the treatment of various
diseases, especially cancer, as one of the leading causes of death worldwide. Nanocarriers …
diseases, especially cancer, as one of the leading causes of death worldwide. Nanocarriers …
[HTML][HTML] Apalutamide and overall survival in prostate cancer
MR Smith, F Saad, S Chowdhury, S Oudard… - European urology, 2021 - Elsevier
Background The phase 3 SPARTAN study evaluated apalutamide versus placebo in
patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate …
patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate …
[HTML][HTML] Genomic hallmarks and structural variation in metastatic prostate cancer
While mutations affecting protein-coding regions have been examined across many
cancers, structural variants at the genome-wide level are still poorly defined. Through …
cancers, structural variants at the genome-wide level are still poorly defined. Through …
Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer
We report herein the discovery of highly potent PROTAC degraders of androgen receptor
(AR), as exemplified by compound 34 (ARD-69). ARD-69 induces degradation of AR protein …
(AR), as exemplified by compound 34 (ARD-69). ARD-69 induces degradation of AR protein …
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
K Raina, J Lu, Y Qian, M Altieri… - Proceedings of the …, 2016 - National Acad Sciences
Prostate cancer has the second highest incidence among cancers in men worldwide and is
the second leading cause of cancer deaths of men in the United States. Although androgen …
the second leading cause of cancer deaths of men in the United States. Although androgen …
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
A Calcinotto, C Spataro, E Zagato, D Di Mitri, V Gil… - Nature, 2018 - nature.com
Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a
condition known as castration-resistant prostate cancer (CRPC). Acquiring a better …
condition known as castration-resistant prostate cancer (CRPC). Acquiring a better …
Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer
Proteolysis targeting chimera (PROTAC) small-molecule degraders have emerged as a
promising new type of therapeutic agents, but the design of PROTAC degraders with …
promising new type of therapeutic agents, but the design of PROTAC degraders with …
Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without …
Abstract Purpose: PI3K–Akt–mTOR and androgen receptor (AR) signaling are commonly
aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN …
aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN …
Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states
H Song, HNW Weinstein, P Allegakoen… - Nature …, 2022 - nature.com
Prostate cancer is the second most common malignancy in men worldwide and consists of a
mixture of tumor and non-tumor cell types. To characterize the prostate cancer tumor …
mixture of tumor and non-tumor cell types. To characterize the prostate cancer tumor …